Bladder Cancer Market

Market Overview:

The 7 major bladder cancer markets reached a value of US$ 3.9 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 5.4 Billion by 2034, exhibiting a growth rate (CAGR) of 3.09% during 2024-2034.

The bladder cancer market has been comprehensively analyzed in IMARC's new report titled "Bladder Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Bladder cancer refers to a type of cancer that occurs in the tissues of the bladder, a hollow structure in the pelvis that stores urine. The most common symptom associated with the ailment is the presence of blood in urine, which may appear bright red or rusty in color. Various other symptoms may include pain or burning during urination, frequent urination, feeling the need to urinate but being unable to do so, lower back pain, etc. The diagnosis of the condition typically involves a combination of medical history, physical examination, and laboratory investigations. Cystoscopy is the most common diagnostic test for bladder cancer, which entails inserting a thin, camera-equipped tube through the urethra and into the bladder. A biopsy may also be performed during the cystoscopy to collect tissue samples for laboratory testing. Several other investigations may include urine tests to look for cancer cells or blood in the urine, imaging procedures like CT scans or MRIs to view the bladder and surrounding tissues, and additional biopsies to determine the stage and grade of the cancer.

The rising incidence of chronic bladder inflammation caused by repeated urinary tract infections and long-term use of a urinary catheter is primarily driving the bladder cancer market. In addition to this, the escalating prevalence of several associated risk factors, such as advancing age, family history, tobacco use, radiation exposure., etc., is also bolstering the market growth. Furthermore, the widespread adoption of fluorescence cystoscopy, since it enhances the accuracy of bladder cancer diagnosis and reduces the need for biopsies, is acting as another significant growth-inducing factor. Additionally, the increasing utilization of intravesical therapy, which enables targeted delivery of medication directly into the bladder, thereby improving treatment effectiveness and minimizing side effects, is also propelling the market growth. Besides this, the emerging popularity of bladder preservation therapy, as it is a less invasive approach that allows patients to keep their bladder and avoid the potential complications of radical cystectomy, is creating a positive outlook for the market. Moreover, the inflating demand for minimally invasive procedures, such as robotic-assisted surgery, on account of their several benefits over traditional open surgery, including shorter hospital stays, lesser pain, and faster recovery time, is expected to drive the bladder cancer market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the bladder cancer market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for bladder cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the bladder cancer market in any manner.

Recent Developments:

• In April 2024, ImmunityBio, Inc. announced that the U.S. FDA approved ANKTIVA (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guerin (BCG) for the therapy of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors.
• In April 2024, Protara Therapeutics, Inc. reported positive results from three-month evaluable CIS patients treated with TARA-002, an investigational cell-based therapy, in high-risk NMIBC, including BCG-unresponsive, BCG-experienced, and BCG-naive patient populations.
• In January 2024, the US Food and Drug Administration approved erdafitinib (Balversa, Janssen Biotech) for adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with prone FGFR3 genetic alterations, as determined by an FDA-approved companion diagnostic test, and disease progression on or after at least one line of prior systemic therapy.
• In July 2023, UroGen Pharma Ltd. reported positive topline findings from its Phase 3 trials ATLAS and ENVISION, which investigated UGN-102 (mitomycin) for intravesical solution in patients with low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). Both the ATLAS and ENVISION trials achieved their major objectives.

Key Highlights:

• According to the most recent GLOBOCAN data, bladder cancer accounts for 3% of all cancer diagnoses worldwide, with a higher prevalence in industrialized countries.
• In the United States, bladder cancer is the sixth most common neoplasm.
• The average age of persons who are diagnosed with bladder cancer is 73 years.
• Approximately nine out of ten persons with bladder cancer are above the age of 55.
• The likelihood of men developing this illness during their lifetime is roughly one in 28.
• For women, the likelihood is approximately one in 89.

Drugs:

BAVENCIO is a prescription medication used to treat a form of bladder or urinary tract cancer known as urothelial carcinoma (UC) that has spread or cannot be removed surgically. BAVENCIO may be used as a maintenance treatment after platinum-containing chemotherapy as the initial treatment.

CG0070 is an intravenous oncolytic immunotherapy agent used for the treatment of bladder cancer. The therapeutic candidate can eliminate cancer cells through two mechanisms: direct cell killing by the virus and immune-mediated cell killing enhanced by GM-CSF.

ANKTIVA (N-803) is a new IL-15 superagonist complex made up of an IL-15 mutant (IL-15N72D) coupled with an IL-15 receptor alpha. It binds with high affinity to IL-15 receptors on NK, CD4, and CD8 T cells. This mimics the normal biological features of dendritic cells and stimulates the development of memory killer T cells that have been precisely trained to recognize cancer cells, resulting in the activation and expansion of these killing cells and long-lasting full response.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the bladder cancer market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the bladder cancer market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current bladder cancer marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the bladder cancer market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the bladder cancer market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the bladder cancer market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of bladder cancer across the seven major markets?
• What is the number of prevalent cases (2018-2034) of bladder cancer by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of bladder cancer by gender across the seven major markets?
• What is the number of prevalent cases (2018-2034) of bladder cancer by type across the seven major markets?
• How many patients are diagnosed (2018-2034) with bladder cancer across the seven major markets?
• What is the size of the bladder cancer patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of bladder cancer?
• What will be the growth rate of patients across the seven major markets?
   

Bladder Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for bladder cancer drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the bladder cancer market?
• What are the key regulatory events related to the bladder cancer market?
• What is the structure of clinical trial landscape by status related to the bladder cancer market?
• What is the structure of clinical trial landscape by phase related to the bladder cancer market?
• What is the structure of clinical trial landscape by route of administration related to the bladder cancer market?